Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Matinas Biopharma Hl (MTNB)

Matinas Biopharma Hl (MTNB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Matinas Biopharma Hl 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER NJ 07921 USA

www.matinasbiopharma.com Employees: 32 P: 908-484-8805

Description:

Matinas BioPharma is a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its LNC platform technology. The Company's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic and orally bioavailable. The Company's lead anti-fungal product candidate, MAT2203, utilizes its proprietary lipid nano-crystal formulation technology for the safe and effective delivery of the broad-spectrum fungicidal agent, amphotericin B. Based on the positive patient clinical data reported in 2017, Matinas is preparing for a potential Phase 2 pivotal trial of MAT2203 for prevention of invasive fungal infections in patients with acute lymphoblastic leukemia.

Key Statistics

Overview:

Market Capitalization, $K 2,950
Enterprise Value, $K -1,890
Shares Outstanding, K 5,087
Annual Sales, $ 1,100 K
Annual Net Income, $ -22,940 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -4,280 K
EBIT, $ -22,010 K
EBITDA, $ -20,960 K
60-Month Beta 1.73
% of Insider Shareholders 9.60%
% of Institutional Shareholders 11.77%
Float, K 4,599
% Float 90.40%
Short Volume Ratio 0.28

Growth:

1-Year Return -94.31%
3-Year Return -98.87%
5-Year Return -99.00%
5-Year Revenue Growth 816.67%
5-Year Earnings Growth 26.67%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.85 on 11/13/24
Next Earnings Date N/A
Earnings Per Share ttm -4.85
EPS Growth vs. Prev Qtr 15.00%
EPS Growth vs. Prev Year 43.33%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-50 on 09/03/24

MTNB Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -123.06%
Return-on-Assets % -94.28%
Profit Margin % -2,085.45%
Debt/Equity 0.00
Price/Sales 2.51
Price/Cash Flow N/A
Price/Book 0.17
Book Value/Share 3.14
Interest Coverage -1.21
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar